Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
David B Sommer & Mark A Stacy. (2008) What’s in the pipeline for the treatment of Parkinson’s disease?. Expert Review of Neurotherapeutics 8:12, pages 1829-1839.
Read now
Read now
Articles from other publishers (30)
Xiao-Zhong Jing, Hui-Jia Yang, Reyisha Taximaimaiti & Xiao-Ping Wang. (2023) Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the
Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease. Current Neuropharmacology 21:5, pages 1224-1240.
Crossref
Crossref
Neelam Upadhyay, Manjari Tripathi, Rakesh Kumar Chaddha, Rashmi Ramachandran, Arunmozhimaran Elavarasi, Gururao Hariprasad & Ravikrishnan Elangovan. (2023) Development of sensitive magnetic nanoparticle assisted rapid sandwich assay(s-MARSA) to monitor Parkinson's disease and Schizophrenia pharmacotherapy. Analytical Biochemistry 667, pages 115082.
Crossref
Crossref
Widya Dwi Aryati, Nabilah Nurtika Salamah, Rezi Riadhi Syahdi & Arry Yanuar. 2019. Neuroprotection. Neuroprotection.
Klaus W. Lange, Yukiko Nakamura, Ning Chen, Jianjun Guo, Shigehiko Kanaya, Katharina M. Lange & Shiming Li. (2019) Diet and medical foods in Parkinson’s disease. Food Science and Human Wellness 8:2, pages 83-95.
Crossref
Crossref
Margherita Torti, Daniele Bravi, Laura Vacca & Fabrizio Stocchi. (2019) Are All Dopamine Agonists Essentially the Same?. Drugs 79:7, pages 693-703.
Crossref
Crossref
Spyros Papapetropoulos, Wenlei Liu, Sridhar Duvvuri, Kathleen Thayer & David L. Gray. (2018) Evaluation of D<sub>1</sub>/D<sub>5</sub> Partial Agonist PF-06412562 in Parkinson’s Disease following Oral Administration. Neurodegenerative Diseases 18:5-6, pages 262-269.
Crossref
Crossref
Ya-Dan Wang, Xiu-Qi Bao, Song Xu, Wen-Wen Yu, Sheng-Nan Cao, Jin-Ping Hu, Yan Li, Xiao-Liang Wang, Dan Zhang & Shi-Shan Yu. (2016) A Novel Parkinson’s Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway. Journal of Medicinal Chemistry 59:19, pages 9062-9079.
Crossref
Crossref
Valentin K. Gribkoff. 2015. The Functions, Disease-Related Dysfunctions, and Therapeutic Targeting of Neuronal Mitochondria. The Functions, Disease-Related Dysfunctions, and Therapeutic Targeting of Neuronal Mitochondria
295
321
.
Darakhshan J. Haleem. (2015) 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson’s disease and schizophrenia. Behavioural Pharmacology 26:1 and 2 - Special Issue, pages 45-58.
Crossref
Crossref
Elena Dragicevic, Christina Poetschke, Johanna Duda, Falk Schlaudraff, Stephan Lammel, Julia Schiemann, Michael Fauler, Andrea Hetzel, Masahiko Watanabe, Rafael Lujan, Robert C. Malenka, Joerg Striessnig & Birgit Liss. (2014) Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. Brain 137:8, pages 2287-2302.
Crossref
Crossref
Manuel de Lera Ruiz, Yeon-Hee Lim & Junying Zheng. (2013)
Adenosine A
2A
Receptor as a Drug Discovery Target
. Journal of Medicinal Chemistry 57:9, pages 3623-3650.
Crossref
Crossref
Bruce N. Rogers & David L. Gray. 2012. Drug Discovery for Psychiatric Disorders. Drug Discovery for Psychiatric Disorders
123
156
.
Brian C. Shook, Stefanie Rassnick, Nathaniel Wallace, Jeffrey Crooke, Mark Ault, Devraj Chakravarty, J. Kent Barbay, Aihua Wang, Mark T. Powell, Kristi Leonard, Vernon Alford, Robert H. Scannevin, Karen Carroll, Lisa Lampron, Lori Westover, Heng-Keang Lim, Ronald Russell, Shawn Branum, Kenneth M. Wells, Sandra Damon, Scott Youells, Xun Li, Derek A. Beauchamp, Kenneth Rhodes & Paul F. Jackson. (2012)
Design and Characterization of Optimized Adenosine A
2A
/A
1
Receptor Antagonists for the Treatment of Parkinson's Disease
. Journal of Medicinal Chemistry 55:3, pages 1402-1417.
Crossref
Crossref
Stefanie C. Linden, Margaret C. Jackson, Leena Subramanian, David Healy & David E.J. Linden. (2011) Sad benefit in face working memory: An emotional bias of melancholic depression. Journal of Affective Disorders 135:1-3, pages 251-257.
Crossref
Crossref
Brian C. Shook & Paul F. Jackson. (2011)
Adenosine A
2A
Receptor Antagonists and Parkinson’s Disease
. ACS Chemical Neuroscience 2:10, pages 555-567.
Crossref
Crossref
Lawrence ElmerRobert A Hauser. (2011) Strategies for Parkinson’s disease care: prevention and management of motor fluctuations. Neurodegenerative Disease Management 1:5, pages 415-430.
Crossref
Crossref
Hai Zhang, Na Ye, Shanglin Zhou, Lin Guo, Longtai Zheng, Zhili Liu, Bo Gao, Xuechu Zhen & Ao Zhang. (2011)
Identification of
N
-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D
2
and Serotonin 5-HT
1A
Dual-Agonist Profile
. Journal of Medicinal Chemistry 54:13, pages 4324-4338.
Crossref
Crossref
Brian C. Shook, Devraj Charavarty, J. Kent Barbay, Aihua Wang, Kristi Leonard, Vernon Alford, Mark Powell, Derek A. Beauchamp, Stefanie Rassnick, Robert Scannevin, Karen Carroll, Nathaniel Wallace, Jeffrey Crooke, Mark Ault, Lisa Lampron, Lori Westover, Kenneth Rhodes & Paul F. Jackson. (2011) Aminomethyl substituted thieno[2,3-d]pyrimidines as adenosine A2A receptor antagonists. MedChemComm 2:10, pages 950.
Crossref
Crossref
Bertil B. FredholmJiang-Fan Chen & Yijuang Chern. 2011. Methylxanthines. Methylxanthines
267
310
.
Leena Subramanian, John Vincent Hindle, Margaret Cecilia Jackson & David E. J. Linden. (2010) Dopamine boosts memory for angry faces in Parkinson's disease. Movement Disorders 25:16, pages 2792-2799.
Crossref
Crossref
Brian C. Shook, Stefanie Rassnick, Melville C. Osborne, Scott Davis, Lori Westover, Jamie Boulet, Daniel Hall, Kenneth C. Rupert, Geoffrey R. Heintzelman, Kristin Hansen, Devraj Chakravarty, James L. Bullington, Ronald Russell, Shawn Branum, Kenneth M. Wells, Sandra Damon, Scott Youells, Xun Li, Derek A. Beauchamp, David Palmer, Mayra Reyes, Keith Demarest, Yuting Tang, Kenneth Rhodes & Paul F. Jackson. (2010)
In Vivo Characterization of a Dual Adenosine A
2A
/A
1
Receptor Antagonist in Animal Models of Parkinson’s Disease
. Journal of Medicinal Chemistry 53:22, pages 8104-8115.
Crossref
Crossref
Mark J. Millan. (2010) From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacology & Therapeutics 128:2, pages 229-273.
Crossref
Crossref
Vincenza Bagetta, Veronica Ghiglieri, Carmelo Sgobio, Paolo Calabresi & Barbara Picconi. (2010) Synaptic dysfunction in Parkinson's disease. Biochemical Society Transactions 38:2, pages 493-497.
Crossref
Crossref
Balaram Ghosh, Tamara Antonio, Juan Zhen, Prashant Kharkar, Maarten E. A. Reith & Aloke K. Dutta. (2009)
Development of (
S
)-
N
6
-(2-(4-(Isoquinolin-1-yl)piperazin-1-yl)ethyl)-
N
6
-propyl-4,5,6,7-tetrahydrobenzo[
d
]-thiazole-2,6-diamine and Its Analogue as a D3 Receptor Preferring Agonist: Potent in Vivo Activity in Parkinson’s Disease Animal Models
. Journal of Medicinal Chemistry 53:3, pages 1023-1037.
Crossref
Crossref
P.A. LeWitt. 2010. Encyclopedia of Movement Disorders. Encyclopedia of Movement Disorders
332
337
.
Alexandra Doehring, Anja Kirchhof & Jörn Lötsch. (2009) Genetic diagnostics of functional variants of the human dopamine D2 receptor gene. Psychiatric Genetics 19:5, pages 259-268.
Crossref
Crossref
Angelo Antonini, Eduardo Tolosa, Yoshikuni Mizuno, Mitsutoshi Yamamoto & Werner H Poewe. (2009) A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. The Lancet Neurology 8:10, pages 929-937.
Crossref
Crossref
Yasuhide Mitsumoto, Shota Kobayashi, Hiroaki Matsushima, Akiko Muroyama & Ikuo Yoshimura. (2009) Oral administration of coenzyme Q10 prevents cytochrome c release from mitochondria induced by 1-methyl-4-phenylpyridinium ion in mouse brain synaptosomes. Neuroscience Letters 463:1, pages 22-25.
Crossref
Crossref
P. Jenner, A. Mori, R. Hauser, M. Morelli, B.B. Fredholm & J.F. Chen. (2009) Adenosine, adenosine A2A antagonists, and Parkinson's disease. Parkinsonism & Related Disorders 15:6, pages 406-413.
Crossref
Crossref
Jean-Louis Peglion, Christophe Poitevin, Clotilde Mannoury La Cour, Delphine Dupuis & Mark J. Millan. (2009) Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors. Bioorganic & Medicinal Chemistry Letters 19:8, pages 2133-2138.
Crossref
Crossref